These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 22365782

  • 1. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B, Celis P, Carr M, Reinhardt J.
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [Abstract] [Full Text] [Related]

  • 2. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [Abstract] [Full Text] [Related]

  • 3. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M, Büttel IC, Schneider CK.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [Abstract] [Full Text] [Related]

  • 4. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P, Schuessler-Lenz M, Ruiz S, Celis P, Reischl I, Menezes-Ferreira M, Flory E, Renner M, Ferry N.
    Adv Exp Med Biol; 2015 Jul; 871():103-30. PubMed ID: 26374215
    [Abstract] [Full Text] [Related]

  • 5. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
    Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
    [Abstract] [Full Text] [Related]

  • 6. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
    Boráň T, Menezes-Ferreira M, Reischl I, Celis P, Ferry N, Gänsbacher B, Krafft H, Lipucci di Paola M, Sladowski D, Salmikangas P.
    Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
    [Abstract] [Full Text] [Related]

  • 7. [Scientific advice by the national and European approval authorities concerning advanced therapy medicinal products].
    Jost N, Schüssler-Lenz M, Ziegele B, Reinhardt J.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1207-14. PubMed ID: 26369763
    [Abstract] [Full Text] [Related]

  • 8. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
    Berger A, Schüle S, Flory E.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
    [Abstract] [Full Text] [Related]

  • 9. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S, Bührer A, Fürst W, Schober-Ladani N.
    Handb Exp Pharmacol; 2024 Jul; 284():367-387. PubMed ID: 37017789
    [Abstract] [Full Text] [Related]

  • 10. Translational research on advanced therapies.
    Belardelli F, Rizza P, Moretti F, Carella C, Galli MC, Migliaccio G.
    Ann Ist Super Sanita; 2011 Jul; 47(1):72-8. PubMed ID: 21430343
    [Abstract] [Full Text] [Related]

  • 11. Regulatory/Scientific Supports for Micro-, Small-, and Medium-Sized Enterprises (SMEs) With Medicinal Products Provided by the PMDA and EMA.
    Kondo H, Shibatsuji M, Yasuda N.
    Ther Innov Regul Sci; 2019 Mar; 53(2):193-198. PubMed ID: 29719977
    [Abstract] [Full Text] [Related]

  • 12. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C, Obach M, Vallano A, Agustí A.
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [Abstract] [Full Text] [Related]

  • 13. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M.
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [Abstract] [Full Text] [Related]

  • 14. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
    Ancans J.
    Front Immunol; 2012 Dec; 3():253. PubMed ID: 22912639
    [Abstract] [Full Text] [Related]

  • 15. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S, Sucić AF, Martinac AI.
    Regul Toxicol Pharmacol; 2010 Dec; 57(2-3):325-32. PubMed ID: 20385190
    [Abstract] [Full Text] [Related]

  • 16. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM, Mariz S, Stoyanova-Beninska V, Celis P, Vamvakas S, Larsson K, Sepodes B.
    Front Med (Lausanne); 2017 Dec; 4():53. PubMed ID: 28560211
    [Abstract] [Full Text] [Related]

  • 17. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L, Zou W, Zhou Z, Zhang T, Greef J, Wang M.
    J Ethnopharmacol; 2014 Oct 28; 156():107-14. PubMed ID: 25169214
    [Abstract] [Full Text] [Related]

  • 18. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W, Stolte F, Reh K.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul 28; 51(7):771-8. PubMed ID: 18584103
    [Abstract] [Full Text] [Related]

  • 19. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
    Brévignon-Dodin L.
    Biomed Mater Eng; 2010 Jul 28; 20(3):121-6. PubMed ID: 20930319
    [Abstract] [Full Text] [Related]

  • 20. Development of a cell-based medicinal product: regulatory structures in the European Union.
    Gálvez P, Clares B, Hmadcha A, Ruiz A, Soria B.
    Br Med Bull; 2013 Jul 28; 105():85-105. PubMed ID: 23184855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.